Priority Medicines
Our research projects are, for a large part, focused on research that is difficult or impossible for individual companies to perform. Our research portfolio is based on the disease areas as specified in Priority Medicines, a report by the World Health Organization (WHO). These projects create knowledge that is important for better, faster and less-expensive development of valuable new medicines. Within TI Pharma's project portfolio, there is a special focus on neglected diseases.
The key objectives of the report are to establish a public health-based pharmaceutical research and development agenda, and to help close the gap between public health needs and the developmental priorities of the pharmaceutical industry. A gap can be identified as those diseases of public health importance for which pharmacotherapy either does not exist or is inadequate. In the report, the WHO has identified a number of research gaps in specific therapeutic indications. TI Pharma devotes special attention to these gaps in its research portfolio.
Click here to view the report of the WHO (in PDF, opens in a new window).